Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J Selling LifeScan Unit for $2.1 Billion

Global investment company Platinum Equity submitted a binding offer to the Johnson & Johnson Family of Companies to buy LifeScan Inc. for $2.1 billion.

Read More »

AMO Pharma Sees Positive Results in Phase II Trials

AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.

Read More »

Adaptimmune Sees Positive Early Results in Cancer Treatment

Shares of Adaptimmune Ltd. surged after the company reported three partial responses in three of the four myxoid/round cell liposarcoma patients the company dosed with its NY-ESO SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells.

Read More »

FDA Gives Go-Ahead for Tetra’s Phase II Trial

Tetra Discovery Partners announced that the U.S. Food and Drug Administration gave the Grand Rapids, Michigan-based company’s Investigational New Drug application for BPN14770 the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders, as well as Alzheimer’s disease.

Read More »

Consolidation Could Be Coming to Pharma Industry

With two major prescription drug supply deals announced within a four-month period, the landscape of pharmacy benefits management is changing dramatically.

Read More »

Ideaya Biosciences Nabs $94 Million in Financing

Two years after securing $46 million in financing from the likes of Celgene and Novartis, South San Francisco-based Ideaya Biosciences completed another successful fundraising round with support from GV (formerly Google Ventures) and Roche Venture Fund.

Read More »

Ionis Partners with Akcea for Rare Diseases

Ionis Pharmaceuticals signed a worldwide license deal with Akcea Therapeutics for the experimental rare disease drugs inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.

Read More »

FDA Places Clinical Hold on DMD Gene Therapy

A U.S. Food and Drug Administration decision to slap a clinical hold on Solid Biosciences’s experimental gene therapy treatment for Duchenne muscular dystrophy sent share prices plunging.

Read More »

Theranos’ Elizabeth Holmes Charged with Fraud

Elizabeth Holmes, the founder of embattled biotech Theranos Inc., and former company president Sunny Balwani were charged with massive fraud by the U.S. Securities and Exchange Commission.

Read More »

Foghorn Therapeutics Launches with $50 Million

Foghorn Therapeutics, based in Cambridge, Massachusetts, officially launched with a $50 million investment from Flagship Pioneering and associated investors.

Read More »

Auris Medical Fails Again in Phase III Trial

Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.

Read More »

Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after the company’s lead drug began Phase I testing, San Diego-based Crinetics Pharmaceuticals Inc. secured $63.5 million in Series B financing.

Read More »

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.

Read More »

Are Life Science Companies Falling Behind Tech Companies?

Tech companies, such as Google, Apple, Facebook, Amazon and others, have been making significant forays into the life sciences. Although many have praised the ambitions, innovation and deep pockets these companies bring to the industry, a new report by global consulting and advisory company EY suggests that life science companies are in danger of falling behind their tech brethren.

Read More »

Proteostasis Therapeutics Snags Breakthrough Designation

The U.S. Food and Drug Administration granted Cambridge, Mass.-based Proteostasis Therapeutics‘ investigational cystic fibrosis add-on therapy Breakthrough Therapy Designation.

Read More »

Keytruda Granted Priority Review for Cervical Cancer

The U.S. FDA accepted Merck & Company’s supplemental Biologics License Application and granted Priority Review for Keytruda (pembrolizumab) in advanced cervical cancer.

Read More »

FDA Halts Advaxis Study Following Patient Death

Shares of Advaxis Inc. were down more than 21 percent in after the company announced that the U.S. FDA halted a Phase I/II trial that uses an AstraZeneca Pharmaceuticals LP drug following the death of a patient.

Read More »

Biogen Buys Schizophrenia Asset from Pfizer

Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.

Read More »

Realm Therapeutics Conjunctivitis Drug Fails Phase II Trial

Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.

Read More »

MyoKardia Reports Positive Results in Heart Study

Shares of MyoKardia climbed after the company revealed positive results from a mid-stage clinical trial for obstructive hypertrophic cardiomyopathy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation